We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo
Medica 2026
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Candidate Drug Kills CRCs with Mutated Tumor Suppressor Gene

By LabMedica International staff writers
Posted on 04 Nov 2016
Image: The protein produced by the adenomatous polyposis coli (APC) tumor suppressor gene (Photo courtesy of Wikimedia Commons).
Image: The protein produced by the adenomatous polyposis coli (APC) tumor suppressor gene (Photo courtesy of Wikimedia Commons).
A candidate small molecule drug for treatment of colorectal cancer acts by blocking cholesterol biosynthesis in a subset of tumor cells that carry a mutated version of a gene that normally suppresses tumor formation.

Mutations in the adenomatous polyposis coli (APC) gene are common in colorectal cancer (CRC) - they are found in more than 80% of colon tumors - and more than 90% of those mutations generate stable truncated gene products.

To identify candidate drugs capable of killing CRC cells with mutated APC, investigators at the University of Texas Southwest Medical Center (Dallas, USA) screened more than 200,000 compounds against a panel of normal human colonic epithelial cells (HCECs) and a series of oncogenically progressed HCECs containing a truncated APC protein.

They reported in the October 19, 2016, online edition of the journal Science Translational Medicine that a small molecule, TASIN-1 (truncated APC selective inhibitor-1), specifically killed cells with APC truncations but spared normal and cancer cells with wild-type APC. TASIN-1 exerted its cytotoxic effects through inhibition of cholesterol biosynthesis.

In vivo administration of TASIN-1 inhibited tumor growth of CRC cells with truncated APC but not APC wild-type CRC cells in xenograft models and in a genetically engineered CRC mouse model with minimal toxicity.

"Even though such mutations are common in colorectal cancer, there are currently not any therapeutics that directly target these types of mutations, so this represents fresh avenues to approach," said senior author Dr. Jerry W. Shay, professor of cell biology at the University of Texas Southwest Medical Center. "Our latest finding confirms that targeting TASINs is a viable approach. Considering the high prevalence of APC mutations in colon cancer patients, targeting truncated APC could be an effective therapeutic strategy for prevention and intervention of colorectal cancer and could potentially be used as a marker for stratifying patients in future personalized medicine clinical trials."

Related Links:
University of Texas Southwest Medical Center

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Platelet Function Analyzer
PL-12
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9

Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more